Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (Q40262479)

19 September 2017

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (English)

1 reference

19 September 2017

0 references

1 reference

1 reference

13

A Eggermont

0 references

Nathalie Chaput

1

N Chaput

0 references

Caroline Robert

17

C Robert

0 references

Emilie Lanoy

15

E Lanoy

0 references

Patricia Lepage

P Lepage

2

0 references

author name string

N Chaput

1

1 reference

19 September 2017

C Coutzac

3

1 reference

19 September 2017

E Soularue

4

1 reference

19 September 2017

K Le Roux

5

1 reference

19 September 2017

C Monot

6

1 reference

19 September 2017

L Boselli

7

1 reference

19 September 2017

E Routier

8

1 reference

19 September 2017

L Cassard

9

1 reference

19 September 2017

M Collins

10

1 reference

19 September 2017

T Vaysse

11

1 reference

19 September 2017

L Marthey

12

1 reference

19 September 2017

V Asvatourian

14

1 reference

19 September 2017

C Mateus

16

1 reference

19 September 2017

F Carbonnel

18

1 reference

19 September 2017

27 March 2017

1 reference

19 September 2017

1 reference

19 September 2017

28

1 reference

19 September 2017

1368-1379

1 reference

19 September 2017

6

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

19 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Systematic review: colitis associated with anti-CTLA-4 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The inflammatory status of old age can be nurtured from the intestinal environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Richness of human gut microbiome correlates with metabolic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Reciprocal interactions of the intestinal microbiota and immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDX108

1 reference

19 September 2017

1 reference